Phase 2 Safety and Efficacy Study of Bevirimat Functional Monotherapy in HIV Treatment-Experienced Patients for 2 Weeks*
Public ClinicalTrials.gov record NCT00511368. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase 2 Dose-escalating, P-C, D-B, Parallel Group Study in HIV Treatment-experienced Patients to Evaluate the Safety, Tolerability and Efficacy of PA103001-04 Administered as Functional Monotherapy for 14 Days *(PART B)
Study identification
- NCT ID
- NCT00511368
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Myrexis Inc.
- Industry
- Enrollment
- 92 participants
Conditions and interventions
Conditions
Interventions
- matching placebo Drug
- Bevirimat Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 31, 2006
- Primary completion
- Jun 30, 2008
- Completion
- Jun 30, 2008
- Last update posted
- Jan 19, 2010
2006 – 2008
United States locations
- U.S. sites
- 18
- U.S. states
- 12
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| UCLA Medical Center | Los Angeles | California | 90035 | — |
| Quest Clinical Research | San Francisco | California | 94115 | — |
| University of Colorado Health Science Center | Denver | Colorado | 80262 | — |
| George Washington University Medical Center | Washington D.C. | District of Columbia | 20037 | — |
| Whitman-Walker Clinic | Washington D.C. | District of Columbia | 20037 | — |
| Gary Richmond | Fort Lauderdale | Florida | 33316 | — |
| Orlando Immunology Center | Orlando | Florida | 32803 | — |
| AIDS Research Consortium of Atlanta, Inc. | Atlanta | Georgia | 30308 | — |
| Northwestern University Feinberg School of Medicine | Chicago | Illinois | 60611 | — |
| The Research Insitute | Boston | Massachusetts | 02215 | — |
| UNC at Chapel Hill | Chapel Hill | North Carolina | 27599 | — |
| University Hospitals of Cleveland | Cleveland | Ohio | 44106 | — |
| Ohio State University Medical Center | Columbus | Ohio | 43210 | — |
| Drexel University College of Medicine | Philadelphia | Pennsylvania | 19102 | — |
| Miriam Hospital/Brown University | Providence | Rhode Island | 02906 | — |
| Central Texas Clinical Research | Austin | Texas | 78705 | — |
| Southwest Infectious Diseases | Dallas | Texas | 75204 | — |
| University of Texas Medical Branch Internal Medicine | Galveston | Texas | 77210-4786 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00511368, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 19, 2010 · Synced Jul 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00511368 live on ClinicalTrials.gov.